Valeant Pharmaceuticals International
Tel: 800-548-5100 or 949-461-6000
About Valeant Pharmaceuticals InternationalValeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
CEO: Joseph C. Papa
CMO: Tage Ramakrishna
CFO: Robert Rosiello
Please click here for clinical trial information.
Please click here for Valeant job opportunities.
953 articles with Valeant Pharmaceuticals International
Metabasis Therapeutics, Inc. Comments On Positive 48 Week HBV Data From Pradefovir Mesylate Phase 2 Study Reported By Valeant Pharmaceuticals International
Valeant Pharmaceuticals International To Announce 2005 Fourth Quarter And Year Results On February 28, 2006
Valeant Pharmaceuticals International Receives FDA Approval Of Less-Restrictive Labeling For Tasmar(R)
Valeant Pharmaceuticals International Receives Non-Approvable Letter From FDA For Labeling Application Of Cannabinoid Cesamet(TM) (CII)
InterMune, Inc. Sharpens Focus On Key Development Programs; Significantly Strengthens Financial Position; Divests Infergen(R) For Up To $135.5 Million In Cash
Metabasis Therapeutics, Inc. Comments On Positive Data Reported At AASLD Late-Breaker Session By Valeant Pharmaceuticals International From Pradefovir Mesylate Phase 2 Study
Par Pharmaceutical Companies, Inc. Announces Agreement With Valeant Pharmaceuticals International To Promote Cesamet